Adjunctive high-dose glycine in the treatment of schizophrenia

International Journal of Neuropsychopharmacology

Volumn 4, Issue 4, 2001, Pages 385-391

  Javitt, Daniel C ^a,b,c   Silipo, Gail ^a   Cienfuegos, Angel ^a   Shelley, Anne Marie ^c   Bark, Nigel ^c   Park, Mohan ^d   Lindenmayer, Jean Pierre ^d   Suckow, Ray ^a   Zukin, Stephen R ^c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

Cognition; Glutamate; Negative symptoms; NMDA receptors; Schizophrenia

Indexed keywords

BRAIN RECEPTOR; CLOZAPINE; GLYCINE; HALOPERIDOL; MESORIDAZINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0035218449     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1461145701002590     Document Type: Article

References (25)

1. The NMDA antagonist model for schizophrenia: Promise and pitfalls
2. Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorus selective detection
3. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection
4. The glutamatergic dysfunction hypothesis for schizophrenia
5. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans
6. Placebo-controlled trial of glycine added to clozapine in schizophrenia
7. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
8. D-cycloserine added to clozapine for patients with schizophrenia
9. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
10. Double-blind, placebo-controlled, crossover trial of D-CyCloserine adjuvant therapy for treatment-resistant schizophrenia
11. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction
12. The role of excitatory amino acids in neuropsychiatric illness
13. Recent advances in the phencyclidine model of schizophrenia
14. Amelioration of negative symptoms in schizophrenia by glycine
15. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
16. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: An open-label trial
17. A highly sensitive and specific radioimmunoassay for quantitation of plasma fluphenazine
18. Glutamate receptor dysfunction and schizophrenia
19. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia
20. A linkage study of the N-methyl-D-aspartate receptor subunit gene loci and schizophrenia in southern African Bantu-speaking families
21. Clozapine plasma levels and convulsions
22. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: Evidence on reversible up-regulation by typical neuroleptics
23. D-Serine added to antipsychotics for the treatment of schizophrenia
24. D-serine added to clozapine for the treatment of schizophrenia